- Oops!Something went wrong.Please try again later.
Leading endocrinology and metabolism academic expert with research focus in pathophysiology and treatment of obesity and type 2 diabetes
Robust business development initiative to build biopharmaceuticals pipeline underway with expectation to announce at least one in-licensing agreement before year end
BEVERLY HILLS, CA / ACCESSWIRE / September 12, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced the appointment of Judith Korner, M.D., Ph.D., to its Scientific Advisory Board for the biopharma business unit of the Company, Applied BioPharma.
“We are pleased to welcome Dr. Korner as a founding member of our Scientific Advisory Board. Over the course of 2019, we have been purposefully focusing our corporate and clinical strategies and the leadership surrounding those efforts. The establishment of our Scientific Advisory Board and the appointment of Dr. Korner as its inaugural member is another noteworthy milestone as we continue to establish Applied as a leader in the endocannabinoid biopharmaceuticals space. Dr. Korner’s expertise and insight will be invaluable as we continue to build a solid foundation from which we can launch future expansion and unlock the full potential of Applied BioPharma,” commented Dr. Raymond Urbanski, Chief Executive Officer.
Dr. Korner currently serves as Professor of Medicine in the Department of Medicine and Division of Endocrinology and Metabolism at New York Presbyterian/ Columbia University Irving Medical Center. Her area of research expertise is focused on the pathophysiology and treatment of obesity and type 2 diabetes. She currently has funding from the National Institutes of Health (NIH) to investigate peptide hormones that control hunger and food intake, particularly in association with bariatric surgery. She was the Principal Investigator of a NIH-funded trial to study the effects of leptin administration after gastric bypass surgery on body weight and neuroendocrine function and was the Principal Investigator at Columbia University of a multi-center randomized trial of medical management vs gastric bypass surgery for the treatment of diabetes. Dr. Korner is also the Director of the Weight Control Center at Columbia University Irving Medical Center that specializes in the medical treatment of obesity or excessive weight gain. She has published original research as well as chapters and review articles on weight regulation and obesity therapy, serves as Vice Chair of the Board of Directors of the American Board of Obesity Medicine, and is a member of several professional organizations including The Obesity Society, The Endocrine Society, The American Diabetes Association, The New York Obesity Research Center and the Diabetes and Endocrinology Research Center at Columbia University. She has shared her expertise in the field of obesity through on-site training and mentoring of students and junior faculty and presentations at conferences world-wide.
Dr. Korner added, “Applied has made great strides in laying a solid foundation for its corporate and clinical development. I am pleased to be an inaugural member of this Scientific Advisory Board for what I believe will be an important Company in the endocannabinoid biopharmaceuticals space. With the strategies in place and multiple near-term milestones ahead, I believe Applied has the potential to significantly impact areas of unmet need and I look forward to leveraging my expertise.”
Dr. Korner received her medical degree at the College of Physicians and Surgeons of Columbia University where she also obtained her Ph.D. in Biochemistry and Molecular Biophysics in the laboratory of Dr. Richard Axel. She completed her internship and residency in Internal Medicine, served as Chief Medical Resident, and completed her fellowship in Diabetes, Endocrinology and Metabolism at Columbia University Medical Center.
The Applied BioPharma business unit is focused on the development and commercialization of novel therapeutics to treat serious diseases by leveraging an industry leading pipeline of endocannabinoid system-targeted drug candidates.
The Company is actively seeking in-license opportunities for Applied BioPharma with the goal of developing an industry leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas. The Applied management team expects to announce at least one in-licensing agreement before year end.
About Applied BioSciences Corp.
Applied BioSciences is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics / biopharmaceuticals and delivering high-quality CBD products as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit the Company’s website.
Safe Harbor Statement
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied Biosciences Corp. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contact:
SOURCE: Applied BioSciences Corp.
View source version on accesswire.com: